ACCME: Let the punishment fit the crime

Share this article:
The ACCME said it is committed to shoring up weaknesses identified by the Senate Finance Committee in its April report.

ACCME said the plan includes exploring enhancements, such as adding a monitoring system that may include direct reporting of abuse or placing trained observers in audiences.

The variety of proposed steps in the five-point plan highlights the difficulty in getting to the root of the Senate concerns.

“The big problem is nobody knows,” said Van Harrison, PhD, an ACCME board member and director of the Office of CME at the University of Michigan. “There's a lack of clear data on how big the problem is and how much effort and resources should be put into it.”

Also mentioned: hastening processes used to manage non-compliant providers. That can take up to nine years now, the Senate found. ACCME chief executive Murray Kopelow, MD, who drafted the plan, indicated he is considering a “graded” response to infractions. He also holds out hope that ACCME's Updated Accreditation Criteria, unveiled one year ago, will improve the issue.

A third area is likely to stimulate the most discussion: management of commercial support. ACCME will discuss the future role of funders, including alternate funding models and “discussions on the value, or impact, of no commercial support.”

“ACCME is really showing a concerted effort to respond to the committee findings. They are also buying time,” said Stephen Lewis, a policy analyst and past CEO of an accredited provider.
ACCME staff first must narrow down a list of priorities and then take it to the board in November.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...